| ||||||
NEWS, PUBLICATIONS, AND RELATED STORIES Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Publication: Cancer Research -- July 1, 2008  Medial Edge Newspaper An international team of researchers led by Mayo Clinic recently designed a technique that uses the body's own cells and a virus to destroy cancer cells that spread from primary tumors to other parts of the body through the lymphatic system. In addition, the team's research indicates that this technology could be the basis for a new cancer vaccine to prevent cancer recurrence. View Related Agreement strengthens relationship and spawns new scientific collaborations "TGen takes seriously our commitment to work toward helping patients with cancer and other disorders. This announcement is another mechanism allowing TGen and Mayo faculty to work bi-directionally in a more seamless fashion," said Jeffrey Trent, Ph.D., TGen's president and scientific director. View Related  Named professorships at Mayo Clinic represent the highest academic distinction for a faculty member. Sandra Gendler, Ph.D., was named the David F. and Margaret T. Grohne Research Professor in Therapeutics for Cancer Research. Richard Vile, Ph.D., a consultant in the Department of Molecular Medicine and Department of Immunology at Mayo Clinic Rochester, was honored with The Richard M. Schulze Family Foundation Professorship.  Research into the B7 molecules has been a "family affair" at Mayo. Many Mayo immunologists have joined together to tackle various aspects of their function and behavior and have discovered how they function. View Related     Until now there were no strongly-predictive molecules for prostate cancer. "This discovery will allow physicians to individualize treatment and observation plans for prostate cancer patients," says Timothy Roth, M.D., a Mayo Clinic urology resident and lead author of the study. "Being able to tell a patient his specific risk after surgery, and perhaps even prior to surgery, will be a huge step forward." View Abstract  Highly effective translational research collaboration continues Mayo Clinic Cancer Center is a national recognition of excellence in education, research and treatment of cancer. The lymphoma SPORE is one of six SPORE cancer research programs at Mayo's locations in Arizona, Florida and Minnesota. Mayo Clinic also has been awarded SPORE grants in brain, breast, pancreatic and prostate cancer, and shares a SPORE for myeloma. View Related   Mayo Clinic Cancer Center had researchers from many disciplines presenting more than 60 oral abstracts and dozens of posters, also educational sessions and other special events throughout the 2007 ASCO program, June 1-5. View Related   The National Institutes of Health chose Mayo Clinic as one of the first 12 institutions to receive Clinical and Translational Science Awards (CTSA) in October 2006. "There are two objects in medical education: to heal the sick and advance the science." - Dr. Charles H. Mayo View Related  Yuan-Ping Pang, Ph.D. established the Computer-Aided Molecular Design Laboratory (CAMDL) to learn more about how biological systems function and to establish models that could lead to new treatments for infectious diseases and cancer. View Related Prognostic enzyme for nasopharyngeal cancer identified "We continue to look for ways to combat health disparities in the United States and throughout the world," said Lewis Roberts, M.B.Ch.B., Ph.D., the study's principal investigator and a gastroenterologist at Mayo Clinic. "Our research into SULF2 suggests a number of promising possibilities for the development of more effective treatments for cancer." View Abstract  Research Lost in Hurricane Katrina. Researchers Return to Mayo to Start Again Cancer vaccines are still considered experimental and so far, research results have been mixed. New studies, such as this, demonstrate that researchers are closing in on designing viable cancer vaccines, the investigators say. View Abstract   From studies reviewing basic laboratory science, to clinical trials and the final translation of that research to individualized patient care, Mayo Clinic Cancer Center has a broad portfolio of presentations at the 2007 AACR meeting. View Related   The collaboration will allow Mayo Clinic and Colorado State to combine expertise in comparative oncology and new treatments for disease. The goal of this collaboration is to bring new diagnostic tests specifically related to cancer and infectious diseases to help us advance biomedical research and bring new diagnostics and therapeutics to patients," says Ronald J. Marler, D.V.M, Ph.D., and associate director for Research/Research Alliances at Mayo Clinic in Arizona. View Related  Mayo Clinic Cancer Center's Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) for prostate cancer research has been renewed for an additional five years. SPORE grants are highly competitive awards given to institutions on the cutting edge of translational research in specific types of cancer. View Related   This annual education event brings cutting-edge research and the clinicians and scientists who study it to those who are interested in women's cancers. View Related Mayo Awarded $72 Million for Clinical and Translational Research "The Mayo Clinic Center for Clinical and Translational Research will coordinate the efforts of our outstanding clinical research education and training programs, our world-class scientists and clinical research investigators, and the vast resources of Mayo Clinic to speed the process of turning our research discoveries into the medications and treatments our patients need and expect," says Robert Rizza, M.D., Mayo Clinic's director for research and the director of the new center. View Related  The Clinical Research Training Program provides a formal education in all aspects of clinical research, including grant-writing, legal and ethical issues, statistics, epidemiology and study design and protocols. "I realized how exciting research can be, and how exciting it is to advance the science." Jon Ebbert, M.D. View Related Immunotherapy has significant potential for eradicating many types of cancer and enabling cancer patients to live normal lives. A federation of 20 Mayo Clinic laboratories with multidisciplinary focus, the Department of Immunology is one of the largest within Mayo Clinic's research domain. It is regarded by peers as one of the top research departments in the country, with a distinguished publishing record. Because its creative collaborations are so numerous and productive, its pathbreaking findings regularly appear in top biomedical journals. View Related   "This collaboration will enable us to work with the Indian Health Service to address health care-related needs specific to Native Americans, ranging from developing research initiatives to address unique problems, to finding ways to improve access to medi View Related  Mayo Clinic researchers have shown that the molecule B7-H4 helps renal cell carcinoma (RCC) grow and spread by blocking the immune system. The findings may one day help physicians predict patient outcome and direct treatment, as well as serve as a target at which to aim new and better therapies for this most lethal urologic malignancy. View Abstract In helping young investigators, Mayo Clinic again is connecting all the dots -- leading back to the same point, the same mission, ongoing and yet unchanged for over a century: the needs of the patient come first. New, young investigators are critical to biomedical research. Their fresh ideas, innovativeness, and enthusiasm are necessary for scientific progress. Yet the steps from a junior research position toward a self-sufficient laboratory can be difficult. Mayo Clinic is dedicated to fostering future, investigators. Here we look at two of them and what Mayo is doing to help. View Related  Robert B. Diasio, M.D., has been appointed Mayo Clinic Cancer Center Director, succeeding Franklyn Prendergast, M.D., Ph.D. Dr. Diasio, who will be based at Mayo Clinic in Rochester, will also direct cancer center activities at Mayo Clinic in Arizona and Mayo Clinic in Jacksonville, Fla. View Related  While the incidence of most cancers has been declining, that of non-Hodgkin's lymphoma has been on the rise. It is the fifth most common type of cancer diagnosed in the United States, with an estimated 300,000 Americans currently living with the disease. Radio-Immunotherapy Holds Promise for Patients with Lymphoma "I'm sorry, Mrs. Wolter, but your cancer is back." Charlotte Wolter had heard this before. The Glencoe, Minn., resident had endured seven months of chemotherapy. And now, after participating in a clinical trial she had hoped would put her cancer into remission, she was hearing the words again. For Wolter and many other patients battling B-cell non-Hodgkin's lymphoma, chemotherapy and radiation often result in tumors shrinking but recurring in the same or other locations. At the same time, there is no cure for the disease. These patients brave difficult treatment regimens, endure a host of side effects, yet still fail to hear those magic words: you're cancer-free. But now a new drug, known as Zevalin, is giving hope to patients who no longer respond to other treatment options. For patients like Wolter, Zevalin appears to be a wish come true. View Related The first radiation therapy and respiratory care baccalaureate classes of Mayo School of Health Sciences and the University of Minnesota will be conferred on Friday, May 12, 2006, at Mayo Clinic. View Related Now that this signal has been identified, new strategies can be generated for enhancing the ability of the immune system to kill tumor cells in patients with cancer. "Because NK cells can communicate different messages -- one that serves health by clearing tumors and viruses and one that serves disease by blocking the response to cancer -- understanding which signals result in effective tumor clearance is a high priority for those of us fighting cancer," explains Paul Leibson, M.D., Ph.D., the Mayo Clinic immunologist and pediatrician who led the study. View Abstract In terms of a medical diagnosis, nothing is more devastating than hearing the "C" word - cancer. But now, ASU and Mayo Clinic are hoping that five different C's will become the best arsenal against the big C. The organizations have teamed up to introduce a new research entity called MAC5. MAC5 is short for the Mayo Clinic - ASU Center for Cancer-related Convergence, Cooperation and Collaboration. View Related  Publication: Journal of Clinical Oncology -- Dec. 20, 2005 Results of a pooled analysis from the North Central Cancer Treatment Group View Related      |
Legal restrictions and terms of use applicable to this site
Use of this site signifies your agreement to the terms of use
Copyright © 2008 Mayo Foundation for Medical Education and Research.